Education
Bachelor of Science, University Kent at Canterbury, UK, 1988. Doctor of Philosophy, University Kent at Canterbury, UK, 1992. Doctor of Science, University Kent at Canterbury, UK, 2013.
Bachelor of Science, University Kent at Canterbury, UK, 1988. Doctor of Philosophy, University Kent at Canterbury, UK, 1992. Doctor of Science, University Kent at Canterbury, UK, 2013.
Adrian has over 25 years experience of in neuroscience research and is Co-Founder and Chief Executive Officer of a neuroscience-oriented bioscience company (Neurolixis) developing clinical-stage drugs for the treatment of Parkinson's disease and Rett syndrome. Prior to joining Neurolixis, he was Director of Neurobiology at Pierre Fabre Laboratories where he led programs that identified novel antipsychotics, antidepressants, and analgesics. Prior to Pierre Fabre, Dr. Newman-Tancredi investigated signal transduction mechanisms of monoamine receptors at the Servier Research Institute.
Drugs characterized in the course of Adrian's work include milnacipran, piribedil, agomelatine, levomilnacipran, and befiradol (NLX-112). In addition, Adrian managed the program that led to the early development of the first-in-class serotonergic "biased agonist", F15599 (NLX-101).
Adrian has published over 170 articles in peer-reviewed journals, co-authored 10 patents on NCEs and given presentations to a wide variety of audiences. He serves on the Editorial Board of the International Journal of Neuropsychopharmacology and as European Councillor of the International Society for Serotonin Research.